02:10 PM EDT, 10/30/2025 (MT Newswires) -- Abeona Therapeutics ( ABEO ) said Thursday its autologous gene therapy Zevaskyn received a permanent Healthcare Common Procedure Coding System J-code from the Centers for Medicare and Medicaid Services.

The new product-specific identifier, J3389 - "Topical administration, prademagene zamikeracel, per treatment" - will take effect on Jan. 1, 2026, the company added.

Zevaskyn is Abeona's autologous gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa, a rare genetic skin disease.

Shares of Abeona Therapeutics ( ABEO ) rose more than 4% in recent trading.

Price: 5.20, Change: +0.21, Percent Change: +4.21